1. Medtech Insight
  2. >>Policy & Regulation

Study Progress Updated To ‘Ongoing’: FDA Publishes Interim Report Three Years Into Essure Study

 
• By Hannah Daniel

In a report on Bayer’s postmarket study of Essure, the FDA says Bayer’s study is back on track with its five-year plan.

• Source: Shutterstock

Bayer’s postmarket study of Essure is back on track after a sharp drop in participants in October 2022, the US Food and Drug Administration said in a three-year interim update.

Essure, a sterilization implant marketed by Bayer, was recalled in 2018 in the US. By the end of 2019, all...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

Blood Sugar Spike Risk Leads To Recall Of Tandem Insulin Pumps

 
• By Brian Bossetta

Tandem Diabetes Care initiated a recall last month of several t:slim X2 insulin pumps due to a “malfunction 16” error that can cause the pumps to shut down. The problem is triggered by wiring within the device speaker.

FTC’s New Healthcare Division Chief Is Former Antitrust Prosecutor

 
• By Malcolm Spicer

Emma Mittelstaedt Burnham prosecuted antitrust violations in healthcare sector in her previous work at DoJ, including leading investigation into antitrust cartels in the generic pharmaceutical industry.

From Prioritizing Funding To Non-Animal Data, FDA Receives A Range Of Comments

 
• By Brian Bossetta

The US FDA received over two dozen comments from stakeholders on the next round of the medical device user fee amendments, which will establish funding for fiscal years 2028 through 2032.